Literature DB >> 8989250

Urinary free cortisol and cortisone determined by high performance liquid chromatography in the diagnosis of Cushing's syndrome.

C L Lin1, T J Wu, D A Machacek, N S Jiang, P C Kao.   

Abstract

To determine the efficacy of cortisol and its metabolite, cortisone, measured simultaneously by high performance liquid chromatography (HPLC) in the diagnosis of Cushing's syndrome, we retrospectively reviewed the histories of 29 surgically proven Cushing's syndrome patients (20 Cushing's disease, 5 ectopic ACTH syndrome, and 4 adrenal Cushing's syndrome) and 6 patients with exogenous Cushing's syndrome. These 35 patients had urinary free cortisol determined by both HPLC and competitive binding methods. The efficacy of the HPLC assay using cortisol alone was equivalent to that of the competitive binding assay; 22 of 29 (76%) patients had increased cortisol. Cortisone also aided in the diagnosis; 25 of 29 (86%) had increased cortisone. Twenty-seven of the 29 (93%) patients had either both cortisone and cortisol (n = 19) or at least 1 of the 2 (n = 8) increased. All 6 patients with exogenous Cushing's syndrome had suppressed urinary free cortisol, cortisone, and the presence of prednisone and prednisolone. In the competitive binding assay, all exogenous Cushing's patients had falsely increased cortisol results. In conclusion, urinary free cortisol plus cortisone determined simultaneously by HPLC added a new dimension to the diagnosis of Cushing's syndrome. It should be considered when exogenous Cushing's syndrome is suspected or when only one urinary cortisol test is allowed to be ordered.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8989250     DOI: 10.1210/jcem.82.1.3687

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

2.  The activity of 11β-hydroxysteroid dehydrogenase type 2 enzyme and cortisol secretion in patients with adrenal incidentalomas.

Authors:  Valentina Morelli; Elisa Polledri; Rosa Mercadante; Volha Zhukouskaya; Serena Palmieri; Paolo Beck-Peccoz; Anna Spada; Silvia Fustinoni; Iacopo Chiodini
Journal:  Endocrine       Date:  2015-10-05       Impact factor: 3.633

3.  Repeated remissions of Cushing's disease due to recurrent infarctions of an ACTH-producing pituitary macroadenoma.

Authors:  Abdullah Alarifi; Ali S Alzahrani; Suzan Abdel Salam; Mohammed Ahmed; Imaduddin Kanaan
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 4.  Pituitary tumor diagnosis and treatment.

Authors:  Paul L Penar; David J Nathan; Muriel H Nathan; Afshin Salsali
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

5.  Isolation and characterization of the monkey UGT2B30 gene that encodes a uridine diphosphate-glucuronosyltransferase enzyme active on mineralocorticoid, glucocorticoid, androgen and oestrogen hormones.

Authors:  Caroline Girard; Olivier Barbier; David Turgeon; Alain Bélanger
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

6.  Oral contraception but not menstrual cycle phase is associated with increased free cortisol levels and low hypothalamo-pituitary-adrenal axis reactivity.

Authors:  N Boisseau; C Enea; V Diaz; B Dugué; J B Corcuff; M Duclos
Journal:  J Endocrinol Invest       Date:  2013-05-22       Impact factor: 4.256

7.  Screening for Cushing's syndrome in obese women with and without polycystic ovary syndrome.

Authors:  P Putignano; M Bertolini; M Losa; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

8.  Cushing's syndrome secondary to isolated micronodular adrenocortical disease (iMAD) associated with rapid onset weight gain and negative abdominal MRI findings in a 3 year old male.

Authors:  Rohan K Henry; Margaret F Keil; Constantine A Stratakis; Patricia Y Fechner
Journal:  J Pediatr Endocrinol Metab       Date:  2010-06       Impact factor: 1.634

Review 9.  Work-up of the functional adrenal mass.

Authors:  Michael D Stifelman; David M Fenig
Journal:  Curr Urol Rep       Date:  2005-02       Impact factor: 2.862

10.  11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess.

Authors:  Stuart A Morgan; Emma L McCabe; Laura L Gathercole; Zaki K Hassan-Smith; Dean P Larner; Iwona J Bujalska; Paul M Stewart; Jeremy W Tomlinson; Gareth G Lavery
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.